Sector News

Sanofi taps Bayer’s Brandicourt for CEO job

February 20, 2015
Life sciences
French pharma group Sanofi confirmed Friday it has appointed Olivier Brandicourt to be its new chief executive, four months after firing his widely-respected predecessor Chris Viehbacher.
Paris-educated and a French citizen, Brandicourt is seen as being more likely to avoid the kind of cultural clashes that ultimately led to the ouster of the German-Canadian Viehbacher in October. Sanofi’s board had accused Viehbacher of going behind its back with a plan for mass lay-offs in France–a politically explosive move for one of the country’s biggest employers.
Brandicourt also has extensive international experience, notably in the U.S., where Sanofi makes a third of its sales. He is currently head of German giant Bayer AG’s global health-care business, but spent much of his career at Pfizer Inc. He only moved to Bayer 17 months ago. Bayer has named Werner Baumann as Brandicourt’s successor at its health-care unit.
Despite a challenging outlook, Sanofi’s shares are testing new record highs, having more than recovered the losses that followed Viehbacher’s departure. Viehbacher had been forced out after warning that its key diabetes segment wouldn’t grow this year due to pressure from competition and to the fact that Lantus, its flagship diabetes drug, will lose patent protection in the U.S. this year.
By Geoffrey Smith
Source: Fortune

Related News

September 18, 2020

Eli Lilly, Amgen join forces to scale production of COVID-19 antibody cocktails

Life sciences

Months of fervid research have whittled away most potential options to treat patients with COVID-19, a group of antibody cocktails still hold promise. Eli Lilly believes so strongly in its contender that it’s […]

September 16, 2020

Takeda unveils new Boston R&D manufacturing center for cell therapy pipeline push

Life sciences

Japanese drugmaker Takeda has trumpeted its plan in recent years to cut billions of dollars in costs and pivot around oncology and rare diseases. A key part of that strategy […]

September 15, 2020

AstraZeneca, Oxford restart stalled COVID-19 test as Pfizer ramps up trial numbers for its vaccine

Life sciences

Just under a week after it stopped its key phase 3 pandemic vaccine test, AstraZeneca and the University of Oxford have been given the green light to restart in the […]